Blood Aβ42/Aβ40 Ratio for Amyloidosis Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting Aβ amyloidosis are limited by expense, invasiveness, and lack of standardization, with blood-based markers not demonstrating significant differences in Aβ42 levels between amyloid-positive and amyloid-negative subjects.
Innovation Solution
Measuring the Aβ42/Aβ40 concentration ratio in blood samples and using a system that provides a probability of detecting Aβ amyloidosis equal to or greater than 85%, with a predetermined threshold calculated using a receiver operating characteristic (ROC) curve to identify amyloid-positive subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If neuroimaging studies are used to detect cerebral Aβ amyloidosis, then detection accuracy is improved, but expense and availability are limited
Solution Approach 1:
The patent uses blood-based Aβ42/Aβ40 ratio as a surrogate marker that copies the diagnostic information obtained from invasive and expensive neuroimaging studies. By measuring the ratio of Aβ42 to Aβ40 in blood samples, the invention creates a simplified diagnostic tool that replicates the ability to detect cerebral amyloidosis without requiring complex imaging equipment
Solution Approach 2:
The patent introduces blood-based Aβ42/Aβ40 ratio measurement as an intermediary diagnostic tool between the gold standard neuroimaging studies and clinical decision-making. This intermediary provides comparable diagnostic accuracy while avoiding the limitations of expense, availability, and complexity associated with neuroimaging
2Measurement precision
If CSF collection is used to measure Aβ42 levels, then biomarker detection is improved, but invasiveness and practitioner availability worsen
Solution Approach 1:
The patent extracts the diagnostic information about cerebral amyloidosis from the invasive CSF compartment and relocates it to the accessible blood compartment. By measuring Aβ42/Aβ40 ratio in blood rather than CSF, the invention eliminates the need for lumbar puncture while preserving the ability to detect amyloidosis
Solution Approach 2:
The patent creates a blood-based copy of the CSF biomarker diagnostic approach. The Aβ42/Aβ40 ratio in blood serves as a surrogate that replicates the diagnostic value of CSF Aβ42 measurement without requiring CSF collection
3Ease of operation
If blood Aβ42 levels are measured, then accessibility is improved, but measurement precision worsens due to lack of significant differences between amyloid-positive and amyloid-negative subjects
Solution Approach 1:
The patent changes the measurement parameter from absolute Aβ42 concentration to the Aβ42/Aβ40 ratio. This parameter transformation enhances the ability to distinguish between amyloid-positive and amyloid-negative subjects, as the ratio provides better discrimination than Aβ42 levels alone
Solution Approach 2:
The patent applies local quality by using ratio measurement that highlights the specific diagnostic information relevant to amyloidosis detection. The Aβ42/Aβ40 ratio selectively emphasizes the pathological changes associated with amyloidosis while minimizing variability from other sources
Data Source
AI summary
The present disclosure provides methods for blood-based examination useful to identify subjects with Aβ amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for Aβ amyloidosis, as well as methods for treating subjects diagnosed with Aβ amyloidosis by the methods disclosed herein.